+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID04268121

Phase II Study of 12-Month Neoadjuvant Chemotherapy with Platinum and Etoposide to Improve Disease-Free Survival in Patients with Localized Digestive Neuroendocrine Carcinomas

Led by GERCOR - Multidisciplinary Oncology Cooperative Group · Updated on 2025-07-23

78

Participants Needed

14

Research Sites

208 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness of a 12-month neoadjuvant chemotherapy treatment in patients with locally differentiated digestive neuroendocrine carcinomas NEC. This phase II study aims to improve relapse-free survival RFS by treating patients with chemotherapy before surgery or chemoradiotherapy, depending on tumor location. A parallel prospective cohort study is also conducted with patients diagnosed during surgery who receive adjuvant chemotherapy without prior neoadjuvant treatment. The study includes two groups one receiving neoadjuvant treatment with 4 cycles of platinum-based chemotherapy carboplatin or cisplatin plus etoposide over 3 months, followed by surgery or chemoradiotherapy and a prospective cohort group undergoing surgery before study entry, followed by 4 cycles of platinum-based chemotherapy plus etoposide as adjuvant treatment. Treatment choices and modalities for radiotherapy are made according to current recommendations and tumor location. Participants will be monitored for relapse-free survival at 12 months and overall survival up to 48 months. Researchers will assess treatment response, surgical outcomes, and any treatment-related severe adverse events. The study involves multiple assessments including imaging scans and follow-ups extending up to 48 months. Patient adherence and safety are closely tracked throughout the study period.

CONDITIONS

Brief Title

Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas

Research Team

A

Anna PELLAT, MD

M

Marie-Line GARCIA-LARNICOL

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here